Login

If you are a member of the general public and not a healthcare professional, NOVELTY study investigator or AstraZeneca Medical employee, please CLICK HERE to see information tailored to you.

Scientific Community

Home > Scientific Community

The NOVELTY Scientific Community brings together the Scientific Committee, the National Principal Investigators and the AstraZeneca science and evidence leads. The Scientific Community is led by Co-Chairs, two external experts: Prof. Helen Reddel and Prof. Alberto Papi, joined by AstraZeneca Co-Chair: Dr Hana Müllerová.

Research proposals are primarily discussed and delivered through WorkStreams aligned around key research themes for the NOVELTY study, described below. Although each WorkStream has its own focus, there is collaboration across WorkStreams in the investigation of research questions that encompass or integrate more than one of these areas.

Biomarkers/-Omics

Aims to investigate how biomarkers, including T2 inflammatory biomarkers, could predict poor outcomes in asthma and/or COPD and to evaluate exploratory, non-T2 biomarkers to assess factors affecting their variability and their ability to identify novel patient phenotypes and treatment targets.

Respiratory Symptoms/PROs

Aims to further understand the patterns of obstructive lung disease and its impact on patients through patient-reported outcomes (PROs), patterns of respiratory symptoms, the relationship between patient-reported and physician-reported severity and disease characteristics and validation of novel PROs.

Physiology/Lung Function

Aims to investigate relationships between lung function assessment and imaging with other clinical characteristics, including physician-assigned diagnosis and severity, symptoms and exacerbations.

Healthcare Interactions

Aims to determine outcomes over time, including among patients using maintenance medications. Also aims to identify baseline clinical characteristics and longitudinal clinical patterns that are associated with healthcare utilisation and burden of disease.

Scientific Committee

Professor Helen Reddel
(Co-Chair)

University of Sydney, Australia
National Principal Investigator, Australia

Professor Helen Reddel
(Co-Chair)

University of Sydney, Australia
National Principal Investigator, Australia

Helen Reddel is Professor of Medicine at the Woolcock Institute of Medical Research, Australia. She is Chair of the Global Initiative for Asthma (GINA) Science Committee and member of the GINA Board of Directors and has led major changes in asthma guidelines.

Professor Reddel’s research focuses on management of chronic lung disease in primary care, collaborative approaches to improve patient care, prescribing and use of respiratory medicines and population monitoring of chronic lung disease.

Professor Alberto Papi
(Co-Chair)

University of Ferrara, Italy
National Principal Investigator, Italy

Professor Alberto Papi
(Co-Chair)

University of Ferrara, Italy
National Principal Investigator, Italy

Alberto Papi is Professor of Respiratory Medicine at the University of Ferrara, Italy, and Director of the Respiratory Unit of the Department of Emergency Medicine, S. Anna University Hospital, Ferrara, Italy. He is also an Honorary Clinical Lecturer at the University of Southampton. He has previously served as a Member of the Asthma Board of the European Academy of Allergy and Clinical Immunology, and Secretary of the Respiratory Infections Group of the European Respiratory Society.

Professor Papi’s research primarily focuses on understanding the mechanisms and treatment of asthma and COPD, especially of airway inflammation, its molecular mechanisms and pharmacological modulation.

Professor Alvar Agustí

University of Barcelona, Spain
National Principal Investigator, Spain

Professor Alvar Agustí

University of Barcelona, Spain
National Principal Investigator, Spain

Alvar Agustí is Director of the Respiratory Institute at Hospital Clinic in Barcelona, and Professor of Medicine at the University of Barcelona. He is a member of the American Thoracic Society and European Respiratory Society (ERS; he has served as a member of the Executive Committee). Professor Agustí has a seat at the Royal Academy of Medicine of the Balearic Islands; he is also an Honorary Fellow of the Royal College of Physicians of Edinburgh, a Fellow of the ERS and a member of the Scientific Committee and Board of Directors of the Global Initiative for Chronic Obstructive Lung Disease.

Professor Agustí’s main research interests include COPD and sleep disorders.

Professor Gary Anderson

University of Melbourne, Australia

Professor Gary Anderson

University of Melbourne, Australia

Gary Anderson is Professor and founding Director of the Lung Health Research Centre at the University of Melbourne, Victoria, Australia. He has served on the National Health and Medical Research Council (NHMRC) Research Committee and on the Board of Directors of the Thoracic Society of Australia and New Zealand (TSANZ) as Chair of the Research Committee. He also serves on the Council of the Australian Lung Foundation.

Professor Anderson’s research focuses on genetic disease models and clinical cohorts to understand molecular mechanisms of asthma and COPD. In 2008, he proposed the widely adopted ‘endotype’ concept in asthma.

Dr Aruna Bansal

Acclarogen Ltd., UK

Dr Aruna Bansal

Acclarogen Ltd., UK

Aruna Bansal is Biostatistician and Founder of Acclarogen Ltd., a consultancy company supporting the pharmaceutical and life science sectors, based in Cambridge, UK. Dr Bansal is providing expertise for the statistical analyses of the NOVELTY study.

Prior to founding Acclarogen, Dr Bansal was Assistant Professor at the University of Utah, and Director and Worldwide Head of Genetic Analysis at GlaxoSmithKline. She has also been appointed Chief Statistician of U-BIOPRED, a Europe-wide 5-year project studying severe asthma.

Professor Richard Beasley

Medical Research Institute of New Zealand, New Zealand

Professor Richard Beasley

Medical Research Institute of New Zealand, New Zealand

Richard Beasley is a physician at Wellington Regional Hospital, New Zealand, Director of the Medical Research Institute of New Zealand and Deputy Chair of the Health Research Council of New Zealand. He is an Adjunct Professor at the University of Otago and Victoria University of Wellington and Visiting Professor at the University of Southampton, UK.

Professor Beasley’s research interests in respiratory medicine are primarily in the fields of epidemiology and clinical management.

Professor Elisabeth Bel

University of Amsterdam, The Netherlands

Professor Elisabeth Bel

University of Amsterdam, The Netherlands

Elisabeth Bel is Professor of Pulmonary Diseases at Amsterdam UMC, University of Amsterdam, The Netherlands. She is a past President of the European Respiratory Society (ERS) and has been a member of the ERS Board and Scientific Committee since 2002.

Professor Bel’s research interests focus on difficult-to-treat, severe types of asthma.

Professor J. Mark FitzGerald

Vancouver Coastal Health Research Institute and University of British Columbia, Canada
National Principal Investigator, Canada

Professor J. Mark FitzGerald

Vancouver Coastal Health Research Institute and University of British Columbia, Canada
National Principal Investigator, Canada

J. Mark FitzGerald is Director of the Centre for Heart and Lung Health at the Vancouver Coastal Health Research Institute and Co-Director of the University of British Columbia (UBC) Institute for Heart and Lung Health. He is also a respiratory physician at The Lung Centre, Vancouver General Hospital, and  former Head of the Respiratory Medicine Divisions at the UBC and Vancouver General Hospital.

Professor FitzGerald is a past President of the Canadian Thoracic Society (CTS) and a past Chair and current member of the Global Initiative for Asthma (GINA) Science Committee, the GINA Executive and the CTS Asthma Assembly.

Professor Christer Janson

Uppsala University, Sweden
National Principal Investigator, Sweden

Professor Christer Janson

Uppsala University, Sweden
National Principal Investigator, Sweden

Christer Janson is Professor at the Department of Medical Sciences: Respiratory, Allergy and Sleep Research at Uppsala University, Sweden. He is Secretary of the Assembly on Occupation and Epidemiology at the European Respiratory Society, a member of the Steering Committee of the European Community Respiratory Health Survey II and III and Project Leader of the Respiratory Health in Northern Europe study.

Professor Janson’s research interests include COPD, asthma and allergy epidemiology, inflammation in these diseases and sleep-disordered breathing.

Professor Barry Make

National Jewish Health and University of Colorado Denver, USA

Professor Barry Make

National Jewish Health and University of Colorado Denver, USA

Barry Make is Co-Director of the COPD Program and Director of Pulmonology Rehabilitation and Respiratory Care at National Jewish Health in Denver, Colorado, USA. He is also Professor of Medicine in the Division of Pulmonary Sciences and Critical Care Medicine at the University of Colorado Denver. Professor Make is a Fellow of the American College of Chest Physicians and the American Association of Cardiovascular and Pulmonary Rehabilitation.

Professor Make’s primary clinical research interest is on the management and outcomes of COPD; he has been recognised as one of Castle Connolly’s Top Doctors in the US for the past 10 years.

Professor Richard Martin

National Jewish Health and University of Colorado Denver, USA

Professor Richard Martin

National Jewish Health and University of Colorado Denver, USA

Richard Martin is Chairman of the Department of Medicine at National Jewish Health, and Professor of Medicine at National Jewish Health and the University of Colorado Denver, USA. He holds the Edelstein Chair in Pulmonary Medicine and is the recipient of the American College of Chest Physicians Distinguished Scholar Award in Respiratory Health.

Professor Martin’s research interests are in adult asthma, including airways inflammation, refractory asthma, nocturnal asthma and the interaction of chronic infections with asthma and COPD.

Professor Ian Pavord

University of Oxford, UK

Professor Ian Pavord

University of Oxford, UK

Ian Pavord is Professor of Respiratory Medicine at the University of Oxford and Honorary Consultant Physician at the Oxford University Hospitals. He is a Fellow of the European Respiratory Society and of the Academy of Medical Science.

Professor Pavord focuses on the clinical aspects of inflammatory airways disease and non-invasive measures of airways inflammation. He has identified several clinically important phenotypes of inflammatory airways disease and has played a lead role in developing new treatments for severe airways disease.

Professor David Price

Observational and Pragmatic Research Institute, Singapore and University of Aberdeen, UK

Professor David Price

Observational and Pragmatic Research Institute, Singapore and University of Aberdeen, UK

David Price is Managing Director of the Observational and Pragmatic Research Institute (a company focused on observational research and real-world evidence), Singapore, and Primary Care Respiratory Society Professor of Primary Care Respiratory Medicine at the University of Aberdeen, UK. He is a past Chair of the research committee of the International Primary Care Respiratory Group and is a member of the executive committee for the international ARIA and EPOS guidelines groups.

Professor Price is extensively involved in respiratory and allergy research, especially ‘real-life’ effectiveness and cost-effectiveness of interventions, clinical trial design, compliance and patient attitudes to their disease.

Professor Mohsen Sadatsafavi

University of British Columbia, Canada

Professor Mohsen Sadatsafavi

University of British Columbia, Canada

Mohsen Sadatsafavi is Associate Professor of Health Outcomes at the University of British Columbia and Associate Director of Research at Collaboration for Outcomes Research and Evaluation.

Professor Sadatsafavi leads the Respiratory Evaluation Sciences Program, a laboratory that is specialised in predictive analytics in asthma and COPD. He has received numerous awards for his work, including the New Investigator Award from the Canadian Institutes of Health Research (CIHR) and the Michael Smith Foundation for Health Research.

Professor Jørgen Vestbo

University of Manchester, UK

Professor Jørgen Vestbo

University of Manchester, UK

Jørgen Vestbo is Professor of Respiratory Medicine at the University of Manchester, UK, and Honorary Consultant at the North West Lung Centre, Manchester. He is President of the European Respiratory Society, and has been influential in developing international guidelines for COPD diagnosis and management.

Professor Vestbo’s research interests are on clinical epidemiology and management of COPD and the impact of treatment on the natural history of COPD.

Dr Hana Müllerová
(AstraZeneca Co-Chair)

AstraZeneca, UK

Dr Hana Müllerová
(AstraZeneca Co-Chair)

AstraZeneca, UK

Hana Müllerová is an industry epidemiologist currently leading a COPD medical evidence group at AstraZeneca, UK. Dr Müllerová has been involved in researching respiratory diseases such as asthma and COPD for nearly 20 years. Her research interests include exacerbations, comorbidities and risk-benefit assessments for new and existing medications for these diseases.

Dr Rod Hughes

AstraZeneca, UK

Dr Rod Hughes

AstraZeneca, UK

Rod Hughes is a trained Respiratory Physician. He worked in the UK National Health Service (NHS) until joining AstraZeneca, UK, in 2017. Dr Hughes’ research interests focus on improving care pathways and assessing novel treatment approaches for patients hospitalised with asthma and COPD. Since joining AstraZeneca, he has worked with clinicians across the world to improve awareness of appropriate assessment and medication use in patients with respiratory diseases.

Dr Sarowar Muhammad Golam

AstraZeneca, Sweden

Dr Sarowar Muhammad Golam

AstraZeneca, Sweden

Sarowar Golam is a Health Economist at AstraZeneca, Sweden and a trained physician. He has worked in the field of respiratory disease for almost 10 years. He has significant experience in the research and development of biologics and inhaled medications for asthma and COPD. Before working for AstraZeneca, he worked at the Karolinska Institute, Sweden, and at the University of York, UK, as a research fellow.

Erin Tomaszewski

AstraZeneca, USA

Erin Tomaszewski

AstraZeneca, USA

Erin Tomaszewski works in Patient-centred Science, AstraZeneca, UK. She has 13 years of experience primarily dedicated to research on patient-reported outcomes (PROs) and the patient experience. She has been involved in regulatory strategy planning and PRO development and implementation. She is also involved in PRO instrument ownership, licensing and distribution; training and management of PRO teams; writing manuscripts and abstracts and implementation of digital solutions capturing the patient experience.

National Principal Investigators

Per Bakke

Norway

Robert Bals

Germany

Pierre-Régis Burgel

France

Wang Chen

China

Bradley Chipps

USA

Ricardo Del Olmo

Argentina

Tim Harrison

UK

Hiro Inoue

Japan

Ho Ju Yoon

South Korea

Carlos Matiz

Colombia

José María Olaguibel

Spain

Marcelo Rabahi

Brazil

Chantal Raherison

France

Luis Adrián Rendón Pérez

Mexico

Maarten van den Berge

The Netherlands

Ulla Weinreich

Denmark

19 PARTICIPATING COUNTRIESa
~12,000 ENROLLED PATIENTSa
80% OF PATIENTS HAVE SPIROMETRY DATAb

You are now leaving: http://aznoveltyproject.com/

By following this link you will be leaving the NOVELTY study website.

Please note that AstraZeneca does not take responsibility for the content displayed on other websites.

Continue Return to NOVELTY study